Study of the Immune Response in Colon Adenocarcinoma (IMCO)

Institut National de la Santé Et de la Recherche Médicale, France

Status: Active, not recruiting

Conditions: Colon Adenocarcinoma

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT03015038

2016-A01102-49 (Other Identifier)

C16-21

Details and patient eligibility

About

Duration of each part of the study per patient:

• Screening: From 1 to 4 weeks
• Sampling period (blood and tissue): 1 day
• Follow-up by patient: 60 months
• Total study duration by patient: 84 months
• Total inclusion duration: 24 months
• Total Follow-up duration: 60 months
• Total study duration: 84 months

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Patients aged 18 or more.
2. Affiliation to a social security scheme
3. Diagnosis of a colon adenocarcinoma.
4. Patient have signed and dated consent of the study before undertaking procedures related to the study.

Exclusion criteria

1. Patients under guardianship / curatorship

2. Following Situations

   • Persons unable to understand, read and / or sign an informed consent
   • Patient with the following functions: investigator or co-investigator, research assistant, pharmacist, study coordinator or having any involvement in the study
   • Uncooperative person or potentially non-compliant for the study and its procedures with predictable difficulties regular monitoring of over 1 year.
   • No affiliation to a social security scheme, a universal medical coverage or any similar plan.

3. Pregnant or lactating women.

4. Patients with HIV seropositivity.

5. Rectal tumor location.